Study protocol for a randomised controlled trial to determine the efficacy of lisdexamfetamine for the treatment of acute methamphetamine withdrawal in inpatient settings

Introduction Harms due to methamphetamine use disorder (MAUD) are rising globally. Untreated withdrawal symptoms perpetuate the cycle of dependence and are a barrier to treatment. There is no pharmacotherapy approved for methamphetamine withdrawal. Lisdexamfetamine (LDX) dimesylate has potential as...

Descripció completa

Dades bibliogràfiques

Autors principals:	Dan I Lubman, Jonathan Brett, Andrew Carr, Paul S Haber, Adrian J Dunlop, Nicholas Lintzeris, Frances R Levin, Nadine Ezard, Rebecca McKetin, Brendan Clifford, Michael Doyle, Krista J Siefried, Nathan Taylor, Michael Christmass, Steven Shoptaw, Shalini Arunogiri, Liam S Acheson, Mark Donoghoe, Jack Nagle
Format:	Artigo
Idioma:	Inglês
Publicat:	BMJ Publishing Group 2025-11-01
Col·lecció:	BMJ Open
Accés en línia:	https://bmjopen.bmj.com/content/15/11/e107242.full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!